protocol amendment

February 8, 2019

IMV Advances Phase 1b/2 Trial of DPX-Survivac Following Positive Feedback from FDA

News

IMV has completed an amendment to the protocol of its Phase 1/2 clinical trial testing a triple combination of DPX-Survivac, epacadostat, and low-dose chemotherapy in recurrent ovarian cancer. The company now ... Read more

March 23, 2018March 23, 2018

Cotinga Looks to Expand COTI-2 Trial to Include Other Therapy Combos

News

Cotinga Pharmaceuticals is seeking approval from the U.S. Food and Drug Administration (FDA) to expand its ongoing Phase 1 trial of COTI-2 to include combination therapies and a broader spectrum of ... Read more